Implications of the 2009 American Joint Committee on Cancer Melanoma Staging and Classification on dermatologists and their patients

Mary Alice Nading, Charles M. Balch, Arthur J. Sober

Research output: Contribution to journalArticle

Abstract

The Melanoma Staging and Classification system was recently revised by the American Joint Committee on Cancer (AJCC) and implemented effective January 2010 with changes reflecting new prognostic data gleaned by the significantly larger patient population studied for the 7th edition. This newest analysis yields important long-term outcome data as many of the patients were followed for nearly 2 decades. Additions to edition 7 of the AJCC Melanoma Staging classification highlight several important prognostic factors, particularly the addition of mitotic rate for classifying thin melanomas, the presence of microtumor burden in lymph nodes for stage III disease, and elevated lactate dehydrogenase levels in patients with distant metastatic disease. Although the basic tumor-nodes-metastases (ie, TNM) cancer classification model remains unchanged in this newest edition, the current AJCC Melanoma Staging System has incorporated the latest prognostic data to accurately stratify patients into staging categories. It is important for clinicians and dermatopathologists to familiarize themselves with these changes so that patients are suitably managed and referred to medical and surgical oncologists when appropriate.

Original languageEnglish (US)
Pages (from-to)142-147
Number of pages6
JournalSeminars in Cutaneous Medicine and Surgery
Volume29
Issue number3
DOIs
StatePublished - Sep 2010

Fingerprint

Neoplasm Staging
Melanoma
Neoplasms
L-Lactate Dehydrogenase
Lymph Nodes
Dermatologists
Neoplasm Metastasis
Population

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

Implications of the 2009 American Joint Committee on Cancer Melanoma Staging and Classification on dermatologists and their patients. / Nading, Mary Alice; Balch, Charles M.; Sober, Arthur J.

In: Seminars in Cutaneous Medicine and Surgery, Vol. 29, No. 3, 09.2010, p. 142-147.

Research output: Contribution to journalArticle

@article{c277119111294c51a5fd4e73319589be,
title = "Implications of the 2009 American Joint Committee on Cancer Melanoma Staging and Classification on dermatologists and their patients",
abstract = "The Melanoma Staging and Classification system was recently revised by the American Joint Committee on Cancer (AJCC) and implemented effective January 2010 with changes reflecting new prognostic data gleaned by the significantly larger patient population studied for the 7th edition. This newest analysis yields important long-term outcome data as many of the patients were followed for nearly 2 decades. Additions to edition 7 of the AJCC Melanoma Staging classification highlight several important prognostic factors, particularly the addition of mitotic rate for classifying thin melanomas, the presence of microtumor burden in lymph nodes for stage III disease, and elevated lactate dehydrogenase levels in patients with distant metastatic disease. Although the basic tumor-nodes-metastases (ie, TNM) cancer classification model remains unchanged in this newest edition, the current AJCC Melanoma Staging System has incorporated the latest prognostic data to accurately stratify patients into staging categories. It is important for clinicians and dermatopathologists to familiarize themselves with these changes so that patients are suitably managed and referred to medical and surgical oncologists when appropriate.",
author = "Nading, {Mary Alice} and Balch, {Charles M.} and Sober, {Arthur J.}",
year = "2010",
month = "9",
doi = "10.1016/j.sder.2010.06.004",
language = "English (US)",
volume = "29",
pages = "142--147",
journal = "Seminars in Cutaneous Medicine and Surgery",
issn = "1085-5629",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Implications of the 2009 American Joint Committee on Cancer Melanoma Staging and Classification on dermatologists and their patients

AU - Nading, Mary Alice

AU - Balch, Charles M.

AU - Sober, Arthur J.

PY - 2010/9

Y1 - 2010/9

N2 - The Melanoma Staging and Classification system was recently revised by the American Joint Committee on Cancer (AJCC) and implemented effective January 2010 with changes reflecting new prognostic data gleaned by the significantly larger patient population studied for the 7th edition. This newest analysis yields important long-term outcome data as many of the patients were followed for nearly 2 decades. Additions to edition 7 of the AJCC Melanoma Staging classification highlight several important prognostic factors, particularly the addition of mitotic rate for classifying thin melanomas, the presence of microtumor burden in lymph nodes for stage III disease, and elevated lactate dehydrogenase levels in patients with distant metastatic disease. Although the basic tumor-nodes-metastases (ie, TNM) cancer classification model remains unchanged in this newest edition, the current AJCC Melanoma Staging System has incorporated the latest prognostic data to accurately stratify patients into staging categories. It is important for clinicians and dermatopathologists to familiarize themselves with these changes so that patients are suitably managed and referred to medical and surgical oncologists when appropriate.

AB - The Melanoma Staging and Classification system was recently revised by the American Joint Committee on Cancer (AJCC) and implemented effective January 2010 with changes reflecting new prognostic data gleaned by the significantly larger patient population studied for the 7th edition. This newest analysis yields important long-term outcome data as many of the patients were followed for nearly 2 decades. Additions to edition 7 of the AJCC Melanoma Staging classification highlight several important prognostic factors, particularly the addition of mitotic rate for classifying thin melanomas, the presence of microtumor burden in lymph nodes for stage III disease, and elevated lactate dehydrogenase levels in patients with distant metastatic disease. Although the basic tumor-nodes-metastases (ie, TNM) cancer classification model remains unchanged in this newest edition, the current AJCC Melanoma Staging System has incorporated the latest prognostic data to accurately stratify patients into staging categories. It is important for clinicians and dermatopathologists to familiarize themselves with these changes so that patients are suitably managed and referred to medical and surgical oncologists when appropriate.

UR - http://www.scopus.com/inward/record.url?scp=78049524421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049524421&partnerID=8YFLogxK

U2 - 10.1016/j.sder.2010.06.004

DO - 10.1016/j.sder.2010.06.004

M3 - Article

C2 - 21051007

AN - SCOPUS:78049524421

VL - 29

SP - 142

EP - 147

JO - Seminars in Cutaneous Medicine and Surgery

JF - Seminars in Cutaneous Medicine and Surgery

SN - 1085-5629

IS - 3

ER -